AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
This brief explains the asset selection logic behind equal weighted indices and how different asset classes impact portfolio balance.
23,793 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
The CLARITY Act moves to a July field hearing in New York, but final passage now hinges on seven Senate Democrats. An...
Retirees are rethinking a longtime rule of thumb: pay off the mortgage before retirement. With rates higher and marke...
Even with a solid nest egg, retirement comes with hidden costs. Explore three expenses you may not be ready for and l...
A wedding venue owner took more than $1 million from unsuspecting couples and investors. This article uncovers how th...
Marbella unveiled a bold 2.0 strategy to pivot from luxury tourism to a European tech hub, courting startups and inte...
SpaceX isn’t your typical public stock, but the question remains: should spacex stock below the IPO price be a buying...
Ripple CEO Brad Garlinghouse says the US CLARITY Act is moving toward passage by April, a development that could end ...
Grok AI’s forecast of a $40K Bitcoin price has ignited a fierce market debate. Analysts say the model’s ultra-bear ca...
Bitcoin surged to an intraday high near $74,000 on a choppy trading day, but traders warn that a sustained drop below...
Berkshire Hathaway disclosed a surprise move this quarter: net selling of big positions and a cash hoard that swelled...
Two durable energy bets stand out in 2026, blending a royalty based producer with a diversified energy fund to weathe...